Author Topic: (Abst.) Premenopausal and postmenopausal cancer risk among MS patients  (Read 70 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8629
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed, October 25, 2016:

PLoS One. 2016 Oct 24;11(10)

Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients

Hajiebrahimi M1,2, Montgomery S1,3,4, Burkill S5, Bahmanyar S5,2.

Author information

1Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
2Department of Public Health, Health Faculty, Golestan University of Medical Sciences, Gorgan, Iran.
3Clinical Epidemiology and Biostatistics, School of Medical Sciences, Írebro University, Írebro, Sweden.
4Department of Epidemiology and Public Health, University College London, London, United Kingdom.
5Center for Pharmacoepidemiology & Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

To investigate risk of premenopausal and postmenopausal breast cancer among multiple sclerosis (MS) patients, considering tumor stage.


The Swedish Patient Register identified 19,330 women with MS between 1968 and 2012, matched individually with a cohort of 193,458 without MS. Matching variables were year of birth, sex, region of residence and vital status at the time of diagnosis. The cancer register identified 471 and 5,753 breast cancer cases among the MS and non-MS cohorts, respectively. Cox proportional hazard models estimated hazard ratios (HR) and 95% confidence intervals (CI) for premenopausal and postmenopausal breast cancer.


Overall risk of postmenopausal breast cancer was 13% higher among MS patients compared with women without MS (HR = 1.13, 95% CI 1.02-1.26). Stratified analyses showed that the risk was statistically significantly increased in women diagnosed between 1968 and 1980 and those who were diagnosed at age 65 or older age. We observed a non-statistically significant risk only for stage 0-1 postmenopausal breast cancer (HR = 1.17, 95% CI 0.93-1.48). MS was not associated with premenopausal breast cancer.


The modest increased risk of postmenopausal breast cancer in women with MS may be due to surveillance bias, where contact with health services for one disease increases the risk of a second diagnosis being recorded.

The abstract can be seen here.
MS Speaks--online for 14 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.


Related Topics

  Subject / Started by Replies Last post
1 Replies
Last post October 25, 2016, 09:09:15 am
by agate
1 Replies
Last post May 17, 2016, 05:25:03 pm
by agate
0 Replies
Last post August 24, 2017, 03:56:38 pm
by agate
1 Replies
Last post October 03, 2019, 07:18:24 pm
by agate
1 Replies
Last post October 12, 2018, 08:34:59 am
by agate